12,372 trials
Diabetes Mellitus, Type 2
Primary: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal…
Schizophrenia
Primary: Safety and Tolerability — 65 number of events
Diabetic Retinopathy
Primary: Mean Duration of Definite Center of Macula-involved Diabetic Macular Edema (DME) — 1.72; 1.69 months per participant — p=0.969
Pneumonia · Idiopathic Pneumonia Syndrome
Primary: Response Rate — 62.5; 66.7 percentage of participants
Lateral Epicondylitis · Tennis Elbow
Primary: McGill Pain Questionnaire — 16.6; 15.7; 14.3; 8.2 units on a scale
Anemia
Primary: Percentage of Participants Who Maintained Average Hemoglobin (Hb) Concentration Within Plus Minus (+/-) 1 Grams Per Deciliter (g/dL) of Their Reference Hb and Between 10…
Hepatitis C Virus
Primary: Percentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 75.0; 91.5…
Polymyositis · Dermatomyositis
Primary: The Primary Endpoint is the Total Dose of Glucocorticoids Administered Between Baseline and the End of Treatment. — 124; 135 mg/kg
Nonalcoholic Fatty Liver Disease
Primary: Number of Patients With Improvement in Liver Histology After Treatment With Exenatide — 8 participants
Phenylketonuria
Primary: Dietary Phenylalanine (Phe) Tolerance at Week 26 — 80.6; 50.1 mg/kg/day
Cannabis Dependence · Marijuana Dependence
Primary: 21 Days of Consecutive Abstinence as Measured by the Time-line Followback. — 18; 17 participants
HIV Infections · Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) — 34.8; 25.4 percentage of participants
Hemophilia B
Primary: Incremental Recovery Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product — 1.0114; 0.9506; 1.0600; 0.7379 (IU/dL)/(IU/kg)
Hypogonadism · Hypogonadotropic Hypogonadism
Primary: Change From Baseline in Log-Transformed Testicular Volume at Week 52 — 2.3 Fold change
Chronic Idiopathic Constipation
Primary: Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 241; 14 Patients